Top

Published in:

Open Access 01-12-2024 | Colorectal Cancer | Research

Prognostic value of creatine kinase (CK)-MB to total-CK ratio in colorectal cancer patients after curative resection

Authors: Lubei Rao, Pingyao Xu, Guiji Zhang, Ruiling Zu, Yajun Luo, Kaijiong Zhang, Ying Yang, Dongsheng Wang, Shuya He, Huaichao Luo, Bo Ye

Published in: BMC Cancer | Issue 1/2024

Abstract

Objectives

This study aimed to evaluate the prognostic significance of postoperative Creatine Kinase type M and B (CK-MB) to total Creatine Kinase (CK) ratio (CK-MB/CK) in colorectal cancer (CRC) patients after radical resection.

Methods

This was a single-center retrospective cohort analysis. Subjects were stage I-III CRC patients hospitalized in Sichuan Cancer Hospital from January 2017 to May 2021. Patients were divided into abnormal group and normal group according to whether the CK-MB/CK ratio was abnormal after surgery. Through a comparative analysis of clinical data, laboratory test results, and prognosis differences between the two groups, we aimed to uncover the potential relationship between abnormal CK-MB > CK results and CRC patients. To gauge the impact of CK-MB/CK on overall survival (OS) and disease-free survival (DFS), we employed the multivariable COX regression and LASSO regression analysis. Additionally, Spearman correlation analysis, logistic regression, and receiver-operating characteristic (ROC) curve analysis were conducted to assess the predictive value of the CK-MB/CK ratio for postoperative liver metastasis.

Results

Cox regression analysis revealed that the CK-MB/CK ratio was a stable risk factors for OS (HR = 3.82, p < 0.001) and DFS (HR = 2.31, p < 0.001). To distinguish hepatic metastases after surgery, the ROC area under the curve of CK-MB/CK was 0.697 (p < 0.001), and the optimal cut-off value determined by the Youden index was 0.347.

Conclusions

Postoperative abnormal CK-MB/CK ratio predicts worse prognosis in CRC patients after radical resection and serves as a useful biomarker for detecting postoperative liver metastasis.

Available only for authorised users

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018 68(6):394–424. https://doi.org/10.3322/caac.21492

Wang R, Lian J, Wang X, Pang X, Xu B, Tang S, Shao J, Lu H. Survival rate of colorectal cancer in China: a systematic review and meta-analysis. Front Oncol. 2023;13(1033154). https://doi.org/10.3389/fonc.2023.1033154

Manfredi S, Bouvier AM, Lepage C, Hatem C, Dancourt V, Faivre J. Incidence and patterns of recurrence after resection for cure of colonic cancer in a well defined population. Br J Surg 2006 93(9):1115–22. https://doi.org/10.1002/bjs.5349

Ying HQ, Liao YC, Sun F, Peng HX, Cheng XX. The role of Cancer-elicited inflammatory biomarkers in Predicting Early Recurrence within Stage II-III Colorectal Cancer patients after Curable Resection. J Inflamm Res 2021 14:115–29. https://doi.org/10.2147/jir.S285129

Riedesser JE, Ebert MP, Betge J. Precision medicine for metastatic colorectal cancer in clinical practice. Ther Adv Med Oncol 2022 14:17588359211072703. https://doi.org/10.1177/17588359211072703

Kudose Y, Shida D, Ahiko Y, Nakamura Y, Sakamoto R, Moritani K, Tsukamoto S, Kanemitsu Y. Evaluation of recurrence risk after curative resection for patients with stage I to III colorectal Cancer using the hazard function: retrospective analysis of a single-institution large cohort. Ann Surg 2022 275(4):727–34. https://doi.org/10.1097/sla.0000000000004058

Soroida Y, Ohkawa R, Nakagawa H, Satoh Y, Yoshida H, Kinoshita H, Tateishi R, Masuzaki R, Enooku K, Shiina S, Sato T, Obi S, Hoshino T, Nagatomo R, Okubo S, Yokota H, Koike K, Yatomi Y, Ikeda H. Increased activity of serum mitochondrial isoenzyme of creatine kinase in hepatocellular carcinoma patients predominantly with recurrence. J Hepatol. 2012;57(2):330–6. https://doi.org/10.1016/j.jhep.2012.03.012CrossRefPubMed

Schlattner U, Kay L, Tokarska-Schlattner M. Mitochondrial proteolipid complexes of creatine kinase. Subcell Biochem. 2018;87:365–408. https://doi.org/10.1007/978-981-10-7757-9_13CrossRefPubMed

Zhang L, Han F, Liu X, Xie C, Tian K, Bi Q, Hao M, Mu X. Macro creatine kinase in an asymptomatic patient: a case report. Clin Chem Lab Med. 2020;59(2):e61–4. https://doi.org/10.1515/cclm-2020-0811CrossRefPubMed

10.

Schlattner U, Tokarska-Schlattner M, Wallimann T. Mitochondrial creatine kinase in human health and disease. Biochim Biophys Acta. 2006;1762(2):164–80. https://doi.org/10.1016/j.bbadis.2005.09.004CrossRefPubMed

11.

Collinson P, Suvisaari J, Aakre KM, Baum H, Duff CJ, Gruson D, Hammerer-Lercher A, Pulkki K, Stankovic S, Langlois MR, Apple FS, Laitinen P. How well do Laboratories adhere to recommended guidelines for cardiac biomarkers management in Europe? The CArdiac MARker Guideline Uptake in Europe (CAMARGUE) study of the European Federation of Laboratory Medicine Task Group on Cardiac markers. Clin Chem 2021 67(8):1144–52. https://doi.org/10.1093/clinchem/hvab066

12.

Alvin MD, Jaffe AS, Ziegelstein RC, Trost JC. Eliminating creatine kinase-myocardial Band Testing in suspected Acute Coronary Syndrome: a value-based quality improvement. JAMA Intern Med 2017 177(10):1508–12. https://doi.org/10.1001/jamainternmed.2017.3597

13.

Kovar FM, Aldrian S, Endler G, Vécsei V, Hajdu S, Heinz T, Wagner OF. CK/CK-MB ratio as an indirect predictor for survival in polytraumatized patients. Wien Klin Wochenschr 2012 124(7–8):245–50. https://doi.org/10.1007/s00508-012-0155-8

14.

Ota T, Hasegawa Y, Murata E, Tanaka N, Fukuoka M. False-positive elevation of CK-MB levels with chest Pain in Lung Adenocarcinoma. Case Rep Oncol. 2020;13(1):100–4. https://doi.org/10.1159/000505724CrossRefPubMedPubMedCentral

15.

Eidizadeh A, von Ahsen N, Friedewald S, Binder L. Macro-CK type 2 in metastatic prostate cancer. Diagnosis (Berl). 2019;6(3):307–9. https://doi.org/10.1515/dx-2018-0039CrossRefPubMed

16.

Annesley T. M., McKenna B. J. Ectopic creatine kinase MB production in metastatic cancer. Am J Clin Pathol. 1983;79(2):255–9. https://doi.org/10.1093/ajcp/79.2.255CrossRefPubMed

17.

Wada Y, Tanigawa J, Ishizaka N. Macro-CK and CK-BB contributing to Sham CK-MB Elevation. Intern Med. 2017;56(11):1449–50. https://doi.org/10.2169/internalmedicine.56.8329CrossRefPubMedPubMedCentral

18.

Chang CC, Liou CB, Su MJ, Lee YC, Liang CT, Ho JL, Tsai HW, Yen TH, Chu FY. Creatine kinase (CK)-MB-to-Total-CK ratio: a Laboratory Indicator for Primary Cancer Screening. Asian Pac J Cancer Prev 2015 16(15):6599–603. https://doi.org/10.7314/apjcp.2015.16.15.6599

19.

Uranbileg B, Enooku K, Soroida Y, Ohkawa R, Kudo Y, Nakagawa H, Tateishi R, Yoshida H, Shinzawa S, Moriya K, Ohtomo N, Nishikawa T, Inoue Y, Tomiya T, Kojima S, Matsuura T, Koike K, Yatomi Y, Ikeda H. High ubiquitous mitochondrial creatine kinase expression in hepatocellular carcinoma denotes a poor prognosis with highly malignant potential. Int J Cancer 2014 134(9):2189–98. https://doi.org/10.1002/ijc.28547

20.

Qian XL, Li YQ, Gu F, Liu FF, Li WD, Zhang XM, Fu L. Overexpression of ubiquitous mitochondrial creatine kinase (uMtCK) accelerates tumor growth by inhibiting apoptosis of breast cancer cells and is associated with a poor prognosis in breast cancer patients. Biochem Biophys Res Commun 2012 427(1):60–6. https://doi.org/10.1016/j.bbrc.2012.08.147

21.

Lin YC, Chen SC, Huang CM, Hu YF, Chen YY, Chang SL, Lo LW, Lin YJ, Chen SA. Clinical features and diagnosis of new malignancy in patients with acute pulmonary embolism and without a history of cancer. J Chin Med Assoc 2020 83(3):245–50. https://doi.org/10.1097/jcma.0000000000000259

22.

McGing PG, Teeling M, McCann A, Kyne F, Carney DN. Non-M CK–a practical measure of creatine kinase isoenzymes in cancer patients. Clin Chim Acta 1990 187(3):309–15. https://doi.org/10.1016/0009-8981(90)90116-a

23.

DeFilippis AP, Chapman AR, Mills NL, de Lemos JA, Arbab-Zadeh A, Newby LK, Morrow DA. Assessment and treatment of patients with type 2 myocardial infarction and Acute Nonischemic Myocardial Injury. Circulation 2019 140(20):1661–78. https://doi.org/10.1161/circulationaha.119.040631

24.

Ruetzler K, Smilowitz NR, Berger JS, Devereaux PJ, Maron BA, Newby LK, de Jesus Perez V, Sessler DI, Wijeysundera DN. Diagnosis and management of patients with myocardial Injury after noncardiac surgery: a Scientific Statement from the American Heart Association. Circulation 2021 144(19):e287–305. https://doi.org/10.1161/cir.0000000000001024

25.

Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, White HD. Fourth Universal Definition of Myocardial Infarction (2018). J Am Coll Cardiol 2018 72(18):2231–64. https://doi.org/10.1016/j.jacc.2018.08.1038

26.

Fagerland M. W. t-tests, non-parametric tests, and large studies–a paradox of statistical practice? BMC Med Res Methodol 2012 12:78. https://doi.org/10.1186/1471-2288-12-78

27.

Hajian-Tilaki K. The choice of methods in determining the optimal cut-off value for quantitative diagnostic test evaluation. Stat Methods Med Res 2018 27(8):2374–83. https://doi.org/10.1177/0962280216680383

28.

Akobeng A. K. understanding diagnostic tests 3: receiver operating characteristic curves. Acta Paediatr. 2007;96(5):644–7. https://doi.org/10.1111/j.1651-2227.2006.00178.xCrossRefPubMed

29.

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021 71(3):209–49. https://doi.org/10.3322/caac.21660

30.

Chen C, Lin X, Lin R, Huang H, Lu F. A high serum creatine kinase (CK)-MB-to-total-CK ratio in patients with pancreatic cancer: a novel application of a traditional marker in predicting malignancy of pancreatic masses? World J Surg Oncol 2023 21(1):13. https://doi.org/10.1186/s12957-023-02903-3

31.

Fatemi SR, Pourhoseingholi MA, Asadi F, Vahedi M, Pasha S, Alizadeh L, Zali MR. Recurrence and five -year survival in colorectal Cancer patients after surgery. Iran J Cancer Prev 2015 8(4):e3439. https://doi.org/10.17795/ijcp.3439

32.

Wang D, Yang Y, Jin L, Wang J, Zhao X, Wu G, Zhang J, Kou T, Yao H, Zhang Z. Prognostic models based on postoperative circulating tumor cells can predict poor tumor recurrence-free survival in patients with stage II-III colorectal cancer. J Cancer 2019 10(19):4552–63. https://doi.org/10.7150/jca.30512

33.

Konishi T, Shimada Y, Hsu M, Jimenez-Rodriguez TL, Cercek R, Yaeger A, Saltz R, Smith L, Nash JJ, Guillem GM, Paty JG, Garcia-Aguilar PB, Gonen J, Weiser M. M. R. Association of Preoperative and Postoperative Serum Carcinoembryonic Antigen and Colon cancer outcome. JAMA Oncol 2018 4(3):309–15. https://doi.org/10.1001/jamaoncol.2017.4420

34.

Hermunen K, Soveri LM, Boisen MK, Mustonen HK, Dehlendorff C, Haglund CH, Johansen JS, Osterlund P. Postoperative serum CA19-9, YKL-40, CRP and IL-6 in combination with CEA as prognostic markers for recurrence and survival in colorectal cancer. Acta Oncol 2020 59(12):1416–23. https://doi.org/10.1080/0284186x.2020.1800086

35.

Abe S, Kawai K, Ishihara S, Nozawa H, Hata K, Kiyomatsu T, Tanaka T, Watanabe T. Prognostic impact of carcinoembryonic antigen and carbohydrate antigen 19 – 9 in stage IV colorectal cancer patients after R0 resection. J Surg Res 2016 205(2):384–92. https://doi.org/10.1016/j.jss.2016.06.078

36.

Sonoda H, Yamada T, Matsuda A, Ohta R, Shinji S, Yokoyama Y, Takahashi G, Iwai T, Takeda K, Ueda K, Kuriyama S, Miyasaka T, Yoshida H. Elevated serum carcinoembryonic antigen level after curative surgery is a prognostic biomarker of stage II-III colorectal cancer. Eur J Surg Oncol 2021 47(11):2880–7. https://doi.org/10.1016/j.ejso.2021.05.041

37.

Loo JM, Scherl A, Nguyen A, Man FY, Weinberg E, Zeng Z, Saltz L, Paty PB. Tavazoie S. F. Extracellular metabolic energetics can promote cancer progression. Cell 2015 160(3):393–406. https://doi.org/10.1016/j.cell.2014.12.018

38.

Cook NR. Quantifying the added value of new biomarkers: how and how not. Diagn Progn Res 2018 2:14. https://doi.org/10.1186/s41512-018-0037-2

Title: Prognostic value of creatine kinase (CK)-MB to total-CK ratio in colorectal cancer patients after curative resection
Authors: Lubei Rao
Pingyao Xu
Guiji Zhang
Ruiling Zu
Yajun Luo
Kaijiong Zhang
Ying Yang
Dongsheng Wang
Shuya He
Huaichao Luo
Bo Ye
Publication date: 01-12-2024
Publisher: BioMed Central
Keywords: Colorectal Cancer
Colorectal Cancer
Metastasis
Biomarkers
Published in: BMC Cancer / Issue 1/2024
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-024-12307-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objectives

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2024

Causal association of sleep traits with the risk of thyroid cancer: A mendelian randomization study

A nomogram based on nutritional and inflammatory parameters to predict DMFS and identify beneficiaries of adjuvant chemotherapy in IVA-stage nasopharyngeal carcinoma

Analysis of the efficacy of upfront brain radiotherapy versus deferred radiotherapy for EGFR/ALK-positive non-small cell lung cancer with brain metastases: a retrospective study

Clinical significance of low expression of CADM3 in breast cancer and preliminary exploration of related mechanisms

A systematic review and meta-analysis on mortality rate following total pelvic exenteration in cancer patients

Magnetic resonance imaging-guided intracranial resection of glioblastoma tumors in patient-derived orthotopic xenografts leads to clinically relevant tumor recurrence

Keynote webinar | Spotlight on antibody–drug conjugates in cancer